Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0376358 (prostate cancer)
 59,338 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Prostatic steroid 5-alpha-reductase gene (SRD5A2) encodes a critical enzyme involved in the conversion of testosterone to dihydrotestosterone. A germline mis-sense substitution (A49T) leads to a variant SRD5A2 protein, which has a 5-fold higher in vitro V(max)than the wild-type protein (Ross et al, 1998; Makridakis et al, 1999). The A49T variant was recently associated with 2.5 to 3.28-fold increased risk of prostate cancer (PC) in African-American and Hispanic men (Makridakis et al, 1999). Also, Jaffe et al (2000) reported an association between A49T and more aggressive disease among Caucasian patients. Here, we report that the prevalence of the A49T variant in 449 Finnish PC patients was 6.0%, not significantly different from 6.3% observed in 223 patients with benign prostatic hyperplasia or 5.8% in 588 population-based controls (odds ratio for PC 1.04, 95% C.I. 0.62-1.76, P = 0.89). There was no association between A49T and the family history of the patients nor with tumour stage or grade. Our results argue against a prominent role of the A49T variant as a genetic risk factor for prostate cancer development and progression in the Finnish population.
 ...
PMID:A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland. 1135 45

The development and introduction in clinical practice of finasteride, the first potent inhibitor of steroid 5-alpha-reductase that inhibits the conversion of testosterone to its active form dihydroxytestosterone, has created the possibility to prevent and treat prostatic disorder by manipulating and lowering the androgens levels in the prostate. Randomised and placebo-controlled trials have demonstrated the benefit of finasteride in men with enlarged prostatic gland owing to benign prostatic hyperplasia in terms of symptoms and urinary flow rate improvements. The Prostate Cancer Prevention Trial has clearly stated the chemopreventive properties of finasteride for prostate cancer but the necessity to provide such preventive therapy to a specific group of men with a higher risk to develop a clinically significant disease is under discussion. Finasteride is administered orally as a single daily dose. We recommend a 5 mg dose.
 ...
PMID:Finasteride for prostatic disease: an updated and comprehensive review. 1904 Mar 31